4-Methyl-2-octyl-5-oxo-2,5-dihydrofuran-3-carboxylic acid | 647830-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢呋喃
• 英文名称: 4-Methyl-2-octyl-5-oxo-2,5-dihydrofuran-3-carboxylic acid
• 英文别名: 4-methyl-2-octyl-5-oxo-2H-furan-3-carboxylic acid
• CAS: 647830-53-3
• 化学式: C₁₄H₂₂O₄
• 分子量: 254.32
• InChiKey: UOGODAKBKBDMCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel compounds, pharmaceutical compositions containing same, and methods of use for same
  申请人：Kuhadja P. Francis

  公开号：US20060241177A1

  公开（公告）日：2006-10-26

  Pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX: R 29 ═H, or C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR 31 , —C(O)OR 31 , —C(O)R 31 , —CH 2 C(O)OR 31 , CH 2 C(O)NHR 31 , where R 31 is H or C 1 -C 10 alkyl, cycloalkyl, or alkenyl; R 30 ═C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl; X 5 ═—OR 32 , or NHR 32 , Where R 32 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R 32 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R 32 group further optionally containing one or more halogen atoms; with the proviso that when R 29 is ═CH 2 , then X 5 is not OH. Also disclosed are compounds within the scope of the formula IX, as well as uses of the pharmaceutical compositions for weight loss, anti-microbial and anti-cancer applications, inhibition of fatty acid synthase and neuropeptide-Y, and the stimulation of the activity of carnitine palmitoyl transferase-1.

  药物组合物，包括药物稀释剂和式 IX 的化合物：R 29 ═H，或 C 1 -C 20 烷基、环烷基、烯基、芳基、芳烷基或烷基芳基，═CHR 31 、-C(O)OR 31 、-C(O)R 31 , -CH 2 C(O)OR 31 , CH 2 C(O)NHR 31 其中 R 31 是 H 或 C 1 -C 10 烷基、环烷基或烯基； R 30 ═C 1 -C 20 烷基、环烷基、烯基、芳基、芳烷基或烷基芳基； X 5 ═-OR 32 或 NHR 32 其中 R 32 是 H、C 1 -C 20 烷基、环烷基、烯基、芳基、芳烷基或烷基芳基，R 32 基团可选择含有羰基、羧基、羧酰胺基、醇基或醚基，R 32 基团还可选择含有一个或多个卤素原子；但当 R 29 是 ═CH 2 则 X 5 不是 OH。还公开了式 IX 范围内的化合物，以及药物组合物在减肥、抗微生物和抗癌、抑制脂肪酸合酶和神经肽-Y 以及刺激肉碱棕榈酰转移酶-1 活性方面的用途。
• NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME
  申请人：Fasgen, LLC

  公开号：EP1534263A2

  公开（公告）日：2005-06-01
• EP1534263A4
  申请人：——

  公开号：EP1534263A4

  公开（公告）日：2006-10-11
• [EN] NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME<br/>[FR] NOUVEAUX COMPOSES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS PROCEDES D'UTILISATION
  申请人：FASGEN LLC

  公开号：WO2004006835A2

  公开（公告）日：2004-01-22

  Pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula (IX): R29 = H, or CI-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR31, -C(O)OR31, - C(O)R31, -CH2C(O)OR31, CH2C(O)NHR31, where R31 is H or C1-C10 alkyl, cycloalkyl, or alkenyl; R30 = C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl; X5 = -OR32, or NHR32, Where R32 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R32 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R32 group further optionally containing one or more halogen atoms; with the proviso that when R29 is =CH2, then X5 is not OH. Also disclosed are compounds within the scope of the formula (IX), as well as uses of the pharmaceutical compositions for weight loss, anti-microbial and anti-cancer applications, inhibition of fatty acid synthase and neuropeptide-Y, and the stimulation of the activity of carnitine palmitoyl transferase-1.